COMMUNIQUÉS West-GlobeNewswire

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

06/03/2025 - 22:02

No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications. SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. ( [...]

Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results

06/03/2025 - 22:05

TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

06/03/2025 - 22:05

Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus ( HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET [...]

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

06/03/2025 - 22:05

– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization – SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company [...]

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

06/03/2025 - 22:05

GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

06/03/2025 - 22:05

Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025 Cash of approximately $68.6 million expected to fund [...]

Jushi Holdings Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

06/03/2025 - 22:05

Full Year 2024 Net Loss of $48.8 Million Compared to Net Loss of $65.1 Million in 2023 Full Year 2024 Adjusted EBITDA of $46.2 Million Compared to $40.8 Million in 2023 Increased Quarterly and Annual Operational Cash [...]

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

06/03/2025 - 22:05

First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target [...]

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

06/03/2025 - 22:09

ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple [...]

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

06/03/2025 - 22:10

– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by FDA award of Fast Track [...]

TerrAscend Reports Fourth Quarter and Full Year 2024 Financial Results

06/03/2025 - 22:10

Fourth Quarter Net Revenue of $74.4 million, up 0.3% from $74.2 million in the third quarter of 2024 Fourth Quarter Gross Profit Margin of 50.2%, up 140 basis points from 48.8% in the third quarter of 2024 Full Year [...]

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

06/03/2025 - 22:10

- Continued progress with lead program, CX-2051 (EpCAM PROBODY ® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 (PROBODY ® [...]

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

06/03/2025 - 22:14

BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for [...]

CooperCompanies Announces First Quarter 2025 Results

06/03/2025 - 22:15

SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. [...]

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

06/03/2025 - 22:16

- Duchenne : Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) [...]

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

06/03/2025 - 22:22

RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release [...]

Monthly information on share capital and company voting rights

06/03/2025 - 22:30

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, March 06, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

06/03/2025 - 22:30

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 mars 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

06/03/2025 - 22:35

Completed enrollment of 5,000 subject Phase 2b NAVIGATE trial Severe flu season enables potential mid-year assessment of efficacy Closed $105.0 million financing with new and existing investors Significantly expanded [...]